July 21 - 28, 2019
Snowmass Village, Colorado, USA
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
AACR has designated this live activity for a maximum of 18.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Friday, September 8, 2019. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available below, and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Our basic understanding of cancer has grown exponentially over the past decade. This expansion has been driven in large part by comprehensive cancer genome characterization, new knowledge of epigenetics and chromatin biology across tumor cell states, enhanced imaging capabilities in both clinical and preclinical contexts, new technologies for high-throughput functional studies, and the emergence of the immune system as a crucial—and therapeutically tractable—modulator of tumor progression.
Despite these impressive advances, their successful translation to the diagnosis, treatment, and prevention of cancer remains challenging. Paradoxically, the same frenzied pace of advances in cancer research today may worsen several obstacles to its successful clinical application. This is because many oncologists have difficulty keeping up with the latest research developments and their potential clinical impact—even in academic settings. The language, methodologies, and new technologies used in patient-oriented research may seem increasingly rarefied to the clinician. Conversely, basic scientists frequently lack knowledge of the salient unanswered medical questions that clinical oncologists face; thus, they may be hampered in their ability to configure fundamental discoveries into clinically meaningful frameworks. As a result, a translational gap exists between basic scientists and clinicians, which is manifested at the conceptual, methodological, and educational levels.
There is a need for investigators who bridge the translational gap. Physician-scientists trained in oncology should represent a natural cohort of investigators to bridge this gap. Toward this end, several lines of evidence indicate that physician-scientists remain an integral component of biomedical research in general and clinical translation in particular. Once properly trained, they are particularly well-suited to conduct the "bench to bedside" and "bedside to bench" translational cancer research essential for improving patient care. Conversely, physician-scientists are not easily replaced by either basic or industry-based investigators. Thus, the need for physician-scientists in oncology, both laboratory-based and clinically based, is particularly pressing now if we are to seize the momentum of opportunities being created by the aforementioned explosion in our basic understanding of cancer.
This workshop will contribute to the training of physician-scientists, a cohort that truly spans from bench to bedside. This training is accomplished through lectures from the top investigators in the field of translational cancer research, who not only illustrate the scientific process through their own research, but provide personal examples of their career paths and advice to trainees.
After participating in this CME activity, physicians should be able to:
Comprehend the principles
of molecular biology andexperimental design in translational cancer research as applicable to physician-scientists.
Understand experimental methods used in molecular oncology and translational cancer research.
Design hypothesis-driven aims and robust experiments through grant writing exercises.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
This activity is supported by Professional Educational grants and will be disclosed at the activity.
Please contact the Office of CME at (215) 440-9300 or firstname.lastname@example.org.